Research News

The ongoing SARS-CoV-2 pandemic has caused an imminent urge for both antiviral therapeutical drugs and vaccines. While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. In the light of the further risk of pandemics in the future, however, there remains need for direct antiviral drugs and treatments. Moreover, emerging immune-evasive, I.e. camouflaged from the immune system, SARS-CoV-2 variants are of concern.

By employing artificial intelligence (AI) and robotics to formulate therapeutic proteins, a team led by Rutgers researchers has successfully stabilized an enzyme able to degrade scar tissue resulting from spinal cord injuries and promote tissue regeneration.

Researchers from Columbia Engineering, Fiocruz’s Center for Technological Development in Health and the Oswaldo Cruz Institute in Brazil, Memorial Sloan Kettering Cancer Center, and Rockefeller University recently reported that, by combining inhibitors of polymerases and exonucleases enzymes that allow SARS-CoV-2 to reproduce--they were able to reduce SARS-CoV-2 replication 10 times more than when using just the polymerase inhibitors.

Recent large population cohort analysis demonstrated that a subset of individuals at high risk for developing type 2 diabetes or cardiovascular diseases can be predicted years before disease incidence. The study is published in Plos Biology.

The research team discovered that drugs used to treat blood pressure unexpectedly increase the effect of opioids that the brain naturally produces. This can fine-tune the function of a specific brain circuit and counteract the addictive properties of opiates like fentanyl, which are used to treat pain.

New research from the University of Exeter reports the largest ever whole-genome sequencing project for the potentially fatal yeast infection Candida glabrata from hospitals across Scotland.

Recent research reported that Ayurvedic medicine BGR-34 is effective in reducing high blood sugar levels and this reflects that the BGR-34 therapy is a more effective drug in the treatment of diabetes.

Researchers find out in a recent study that omalizumab provides benefit to patients with moderate to severe allergic asthma, regardless of body mass index.

Bharat Biotech is in the process of bringing out a vaccine against tuberculosis and soon the firm will sign a MoU with another firm for technology.

"Our honourable Prime Minister has got an agenda of 2025 for the eradication of tuberculosis. I think we are in that direction. But we don't have the technology so we are partnering with somebody else. On that matter we should be announcing soon," Krishna Ella, Chairman and Managing Director said in BioAsia 2022.